Search Results - "Dmytro, Trukhin"

Pembrolizumab plus either epacadostat or placebo for cisplatin-ineligible urothelial carcinoma: results from the ECHO-307/KEYNOTE-672 study by Necchi, Andrea, Van der Heijden, Michiel S, Trukhin, Dmytro, Peer, Avivit, Gurney, Howard, Alekseev, Boris Y, Parnis, Francis X, Leibowitz, Raya, De Santis, Maria, Grivas, Petros, Clark, Jason, Munteanu, Mihaela, Kataria, Ritesh, Jia, Calvin, Balar, Arjun V, de Wit, Ronald

“…Indoleamine 2,3- dioxygenase 1 (IDO1) is an immunosuppressive enzyme that has been correlated with shorter disease-specific survival in patients with…”
Get full text

Effect of Amplitude on the Surface Dilational Visco-Elasticity of Protein Solutions by Kovalchuk, Volodymyr, Aksenenko, Eugene, Trukhin, Dmytro, Makievski, Alexander, Fainerman, Valentin, Miller, Reinhard

“…Harmonic drop surface area oscillations are performed at a fixed frequency (0.1 Hz) to measure the dilational visco-elasticity for three proteins: β-casein…”
Get full text

Mixed Protein/Hexane Adsorption Layers Formed at the Surface of Protein Solution Drops Surrounded by Hexane Vapor by Miller, Reinhard, Aksenenko, Eugene V., Kovalchuk, Volodymyr I., Trukhin, Dmytro V., Tarasevich, Yuri I., Fainerman, Valentin B.

“…The surface tension of aqueous solution drops of ß‐casein, ß‐lactoglobulin, and human serum albumin at the interface to air and hexane saturated air are…”
Get full text

Durvalumab ± Tremelimumab + Platinum-Etoposide in Extensive-Stage Small Cell Lung Cancer (CASPIAN): Outcomes by PD-L1 Expression and Tissue Tumor Mutational Burden by Paz-Ares, Luis, Garassino, Marina Chiara, Chen, Yuanbin, Reinmuth, Niels, Hotta, Katsuyuki, Poltoratskiy, Artem, Trukhin, Dmytro, Hochmair, Maximilian J, Özgüroğlu, Mustafa, Ji, Jun Ho, Statsenko, Galina, Conev, Nikolay, Bondarenko, Igor, Havel, Libor, Losonczy, György, Xie, Mingchao, Lai, Zhongwu, Godin-Heymann, Nadia, Mann, Helen, Jiang, Haiyi, Shrestha, Yashaswi, Goldman, Jonathan W

“…In the CASPIAN trial, first-line durvalumab plus platinum-etoposide (EP) significantly improved overall survival (OS) versus EP alone in extensive-stage small…”
Get full text

Bevacizumab biosimilar and reference bevacizumab in subjects with stage IIIB/IV no squamous non-small cell lung cancer (NSCLC) (STELLA study): Results for the primary endpoint in a confirmatory, double-blind, randomized, controlled study by Millan, Susana, Trukhin, Dmytro, Kolesnik, Oleksii, Poddubskaya, Elena, Zoran, Andric, Bondarenko, Igor, Shevnia, Serhii, Bullo, Felicitas, Sarnago, Cristina

“…Abstract only e21542 Background: MB02 is a proposed biosimilar of the reference bevacizumab. A multinational, double-blind, randomized, parallel group clinical…”
Get full text

A phase III, randomized, double-blind, multicenter study to compare the efficacy, safety, pharmacokinetics, and immunogenicity between SB8 (proposed bevacizumab biosimilar) and reference bevacizumab in patients with metastatic or recurrent nonsquamous non-small cell lung cancer by Reck, Martin, Luft, Alexander, Bondarenko, Igor, Shevnia, Serhii, Trukhin, Dmytro, Kovalenko, Nadezhda V., Vacharadze, Kakha, Andrea, Fülöp, Hontsa, Anatoliy, Choi, Jihye, Shin, Donghoon

“…•SB8 and reference bevacizumab (BEV) were equivalent per the risk ratio of best ORR.•Survival outcomes further supported the biosimilarity between SB8 and…”
Get full text

Patient-reported outcomes with first-line durvalumab plus platinum-etoposide versus platinum-etoposide in extensive-stage small-cell lung cancer (CASPIAN): a randomized, controlled, open-label, phase III study by Goldman, Jonathan W., Garassino, Marina Chiara, Chen, Yuanbin, Özgüroğlu, Mustafa, Dvorkin, Mikhail, Trukhin, Dmytro, Statsenko, Galina, Hotta, Katsuyuki, Ji, Jun Ho, Hochmair, Maximilian J., Voitko, Oleksandr, Havel, Libor, Poltoratskiy, Artem, Losonczy, György, Reinmuth, Niels, Patel, Nikunj, Laud, Peter J., Shire, Norah, Jiang, Haiyi, Paz-Ares, Luis

“…•In CASPIAN, first-line durvalumab + EP improved OS vs EP in patients with ES-SCLC.•Patient-reported outcomes (PROs) were prespecified secondary…”
Get full text

Bevacizumab biosimilar (MB02) and reference bevacizumab in patients with stage IIIB/IV non-squamous non-small cell lung cancer (NSCLC) (STELLA study): Multiple Imputation analysis by Trukhin, Dmytro, Poddubskaya, Elena, Zoran, Andric, Bondarenko, Igor, Shevnia, Serhii, Zaric, Bojan, Bellala, Ravishankar, Charoentum, Chaiyut, Perez, Luis, Bullo, Felicitas, Garcia, Fernanda

“…Abstract only e15003 Background: Stella Trial is a phase III, multinational, double-blind and randomized study to confirm clinical similarity between MB02 and…”
Get full text

Efficacy, Safety, and Immunogenicity of HLX02 Compared with Reference Trastuzumab in Patients with Recurrent or Metastatic HER2-Positive Breast Cancer: A Randomized Phase III Equivalence Trial by Xu, Binghe, Zhang, Qingyuan, Sun, Tao, Li, Wei, Teng, Yue’e, Hu, Xichun, Bondarenko, Igor, Adamchuk, Hryhoriy, Zhang, Liangming, Trukhin, Dmytro, Wang, Shusen, Zheng, Hong, Tong, Zhongsheng, Shparyk, Yaroslav, Wang, Qingyu

“…Background HLX02 is an approved biosimilar of trastuzumab. Objective This study aimed to evaluated the efficacy, safety, and immunogenicity of HLX02 compared…”
Get full text

TX05-03e: Adjuvant treatment following neoadjuvant treatment and surgical resection in TX05-03, a trial comparing the safety, efficacy, and immunogenicity of trastuzumab biosimilar candidate (TX05) with originator trastuzumab in HER2+ EBC by Krivorotko, Petr, Manikhas, Alexey, Poddubskaya, Elena, Osinsky, Dmitry, Gopichand, Mamillapalli, Vasilyev, Alexander, Moiseenko, Fedor Vladimirovich, Trukhin, Dmytro, Alarcon-Rozas, Ashley E., Bardakov, Hryhoriy, Haynes, Tori, Lai, Jennifer, Mills, Bonnie J.

“…LBA511 Background: TX05 is being developed as a biosimilar to trastuzumab. We previously reported results of a Phase III study (TX05-03) comparing the efficacy…”
Get full text

Efficacy and Safety of Bevacizumab Biosimilar FKB238 Versus Originator Bevacizumab: Results from AVANA, a Phase III Trial in Patients with Non-Squamous Non-Small-Cell Lung Cancer (non-sq-NSCLC) by Syrigos, Konstantinos, Abert, Istvan, Andric, Zoran, Bondarenko, Igor N, Dvorkin, Mikhail, Galic, Kristina, Galiulin, Rinat, Kuchava, Vladimer, Sriuranpong, Virote, Trukhin, Dmytro, Zhavrid, Edvard, Fu, Dongyue, Kassalow, Laurent M, Jones, Stephanie, Bashir, Zahid

“…Background Bevacizumab is an antiangiogenic recombinant humanized monoclonal antibody that inhibits tumor growth. FKB238, a bevacizumab biosimilar, has…”
Get full text

Durvalumab (D) +/- tremelimumab (T) + chemotherapy (CT) in first-line (1L) metastatic (m) NSCLC: AE management in POSEIDON by Cho, Byoung Chul, Reinmuth, Niels, Luft, Alexander, Alatorre-Alexander, Jorge, Geater, Sarayut Lucien, Trukhin, Dmytro, Kim, Sang-We, Ursol, Grygorii, Hussein, Maen A., Lim, Farah Louise, Yang, Cheng-Ta, Araujo, Luiz H., Saito, Haruhiro, Marotti, Miriam, Barrett, Karen, Shi, Xiaojin, Peters, Solange, Garon, Edward B., Mok, Tony S. K., Johnson, Melissa Lynne

“…9035 Background: In the Phase 3 POSEIDON study in 1L mNSCLC, adding T to D+CT resulted in statistically significant improvements in PFS and OS vs CT. No new…”
Get full text

Clinical efficacy and safety of the BAT1706 (proposed bevacizumab biosimilar) compared with reference bevacizumab in patients with advanced nonsquamous NSCLC: A randomized, double-blind, phase III study by Chen, Likun, Trukhin, Dmytro, Kolesnik, Oleksii, Gomez Rangel, Jose David David, Cil, Timucin, Li, Xingya, Cicin, Irfan, Kobziev, Oleh, Shen, Yihong, Liu, Zhihua, Oleksandr, Ivashchuk, Ozyilkan, Ozgur, Igor, Bondarenko, Ursol, Grygorii, Chen, Jun, Oleksandr, Kostiuk, Chen, Zhendong, Zhang, Helong, Tural, Deniz, Zhang, Li

“…9041 Background: A Randomized, Double-blind, Phase III Study was conducted to confirm clinical similarity between BAT1706, a proposed biosimilar to reference…”
Get full text

O11-5 Durvalumab(D) ± tremelimumab(T) + platinum-etoposide(EP) in 1L ES-SCLC: Characterization of long-term benefit in CASPIAN by Saito, Haruhiro, Goldman, Jonathan W., Garassino, Marina Chiara, Chen, Yuanbin, Reinmuth, Niels, Hotta, Katsuyuki, Poltoratskiy, Artem, Trukhin, Dmytro, Hochmair, Maximilian J., Özgüroğlu, Mustafa, Ji, Jun Ho, Statsenko, Galina, Voitko, Oleksandr, Conev, Nikolay V., Bondarenko, Igor, Spencer, Stuart, Xie, Mingchao, Jones, Stephanie, Franks, April, Shrestha, Yashaswi, Paz-Ares, Luis

Get full text

A Brief Report of Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: Outcomes by Tumor PD-L1 Expression in the Phase 3 POSEIDON Study by Garon, Edward B, Cho, Byoung Chul, Luft, Alexander, Alatorre-Alexander, Jorge, Geater, Sarayut Lucien, Trukhin, Dmytro, Kim, Sang-We, Ursol, Grygorii, Hussein, Maen, Lim, Farah Louise, Yang, Cheng-Ta, Araujo, Luiz Henrique, Saito, Haruhiro, Reinmuth, Niels, Kohlmann, Milena, Lowery, Caitlin, Mann, Helen, Peters, Solange, Mok, Tony S, Johnson, Melissa L

Get full text

Durvalumab ± tremelimumab + platinum-etoposide in first-line extensive-stage SCLC (ES-SCLC): Updated results from the phase III CASPIAN study by Paz-Ares, Luis G., Dvorkin, Mikhail, Chen, Yuanbin, Reinmuth, Niels, Hotta, Katsuyuki, Trukhin, Dmytro, Statsenko, Galina, Hochmair, Maximilian, Özgüroğlu, Mustafa, Ji, Jun Ho, Voitko, Oleksandr, Poltoratskiy, Artem, Verderame, Francesco, Havel, Libor, Bondarenko, Igor, Armstrong, Jon, Byrne, Natalie, Jiang, Haiyi, Goldman, Jonathan Wade

“…Abstract only 9002 Background: CASPIAN is an open-label, Phase 3 study of durvalumab (D) ± tremelimumab (T) + etoposide and either cisplatin or carboplatin…”
Get full text

First-line durvalumab plus platinum-etoposide in extensive-stage (ES)-SCLC (CASPIAN): Impact of brain metastases on treatment patterns and outcomes by Chen, Yuanbin, Paz-Ares, Luis G., Dvorkin, Mikhail, Trukhin, Dmytro, Reinmuth, Niels, Garassino, Marina Chiara, Statsenko, Galina, Voitko, Oleksandr, Hochmair, Maximilian, Özgüroğlu, Mustafa, Verderame, Francesco, Havel, Libor, Losonczy, György, Conev, Nikolay, Hotta, Katsuyuki, Ji, Jun Ho, Broadhurst, Helen, Byrne, Natalie, Thiyagarajah, Piruntha, Goldman, Jonathan Wade

“…Abstract only 9068 Background: In the Phase 3, randomized, open-label CASPIAN study, first-line durvalumab (D) added to etoposide plus either cisplatin or…”
Get full text

Efficacy, Safety and Immunogenicity of MB02 (Bevacizumab Biosimilar) versus Reference Bevacizumab in Advanced Non-Small Cell by Trukhin, Dmytro, Poddubskaya, Elena, Andric, Zoran, Makharadze, Tamta, Bellala, Ravi Shankar, Charoentum, Chaiyut, Yañez Ruiz, Eduardo P, Fulop, Andrea, Hyder Ali, Irfhan Ali, Syrigos, Kostas, Katgi, Nuran, Chuken, Yamil Alonso Lopez, Rumyana, Ilieva, Reyes-Igama, Jasmin, Costamilan, Rita De cassia, García, Ana Del Campo, Florez, Amalia, Paravisini, Alexandra, Millan, Susana

“…Background MB02 (bevacizumab biosimilar) showed similar structural, functional, and pharmacokinetic properties to reference bevacizumab (Avastin;…”
Get full text

Efficacy and safety of the proposed bevacizumab biosimilar BAT1706 compared with reference bevacizumab in patients with advanced nonsquamous non‐small cell lung cancer: A randomized, double‐blind, phase III study by Chen, Likun, Rangel, Jose David Gomez, Cil, Timucin, Li, Xingya, Cicin, Irfan, Shen, Yihong, Liu, Zhihua, Ozyilkan, Ozgur, Igor, Bondarenko, Chen, Jun, Oleksandr, Kostiuk, Chen, Zhendong, Zhang, Helong, Fu, Ziyi, Dong, Qingfeng, Song, Shuqiang, Yu, Jin‐Chen, Zhang, Li, Hryhoriy, Adamchuk, Karaoglu, Aziz, Hryhoriy, Bardakov, Gao, Beili, Oksuzoglu, Berna, Bilir, Cemil, Jordaan, Christa, Hu, Chunhong, Jacobs, Conrad, Tural, Deniz, Erdem, Dilek, Trukhin, Dmytro, Huang, Dongning, Soto, Francisco Alejo Medina, Igor, Galaychuk, Ursol, Grygorii, Liu, Hailong, Harputluoglu, Hakan, Coskun, Hasan Senol, Cinkir, Havva Yesil, Zhang, Helong, Ma, Hu, Zhao, Hui, Zhu, Huili, Cicin, Irfan, Sokur, Iryna, Sinielnikov, Ivan, Oleksandr, Ivashchuk, Fang, Jian, Shi, Jianhua, Tuohayi, Jiazina, Gao, Jinghua, Peng, Jiyong, Rangel, Jose David Gomez, Lira, Jose Luis Martinez, Chen, Jun, Lu, Junguo, Yao, Juntao, Oleh, Kobziev, Oleksandr, Kostiuk, Anna, Kryzhanivska, Chen, Lei, Cai, Li, Zhang, Li, Zhang, Liangming, Chen, Likun, Syvak, Liubov, Jiang, Liyan, Dupper, Louis, Dreosti, Lydia, Gumus, Mahmut, Artac, Mehmet, Kaplan, Muhammet, Lisovska, Natalya, Kolesnik, Oleksii, Olmez, Omer, Altundag, Ozden, Tanriverdi, Ozgur, Olga, Ponomarova, Li, Qi, Yu, Qitao, Mendoza, Rene Lazaro Gonzalez, Andriy, Rusyn, Wang, Senming, Xu, Shen, Shou, Tao, Yi, Tienan, Cil, Timucin, Li, Wei, Guo, Weidong, Zhao, Weiqing, Yao, Wenxiu, Li, Xingya, Zhao, Yanqiu, Shparyk, Yaroslav, Hotko, Yevhen, Shen, Yihong, Zhang, Yiping, Zheng, Zhendong, Wu, Zhengdong, Liu, Zhihua, Wang, Ziping

“…Background BAT1706 is a proposed biosimilar of bevacizumab (Avastin®). We aimed to compare the efficacy and safety of BAT1706 with that of EU‐sourced reference…”
Get full text

Phase III study of vinflunine plus gemcitabine versus paclitaxel plus gemcitabine in the first-line treatment of anthracycline pretreated advanced breast cancer by Llombart, Antonio, Espie, Marc, Ranade, Anantbhushan, Trukhin, Dmytro, Hegg, Roberto, Del Giglio, Auro, Paridaens, Robert, Staroslawska, Elzbieta, Veyret, Corinne, Sakaeva, Dina, Gomez, Henry Leonidas, Lokanatha, Dasappa, Lerzo, Guillermo Luis, Shewalkar, Balaji Keshavrao, Talbot, Denis Charles, Santoro, Armando, Roche, Henri Hubert

“…Abstract only…”
Get full text